A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
DRUG: Repotrectinib|DRUG: Crizotinib
Progression-free Survival (PFS) as per Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Up to approximately 41 months
Overall Survival (OS), Up to approximately 41 months|Overall Response Rate (ORR) as per BICR according to RECIST v1.1, Up to approximately 41 months|ORR as per Investigator according to RECIST v1.1, Up to approximately 41 months|Duration of Response (DOR) as per BICR according to RECIST v1.1, Up to approximately 41 months|DOR as per Investigator according to RECIST v1.1, Up to approximately 41 months|Time to Response (TTR) as per BICR according to RECIST v1.1, Up to approximately 41 months|TTR as per Investigator according to RECIST v1.1, Up to approximately 41 months|PFS as per Investigator according to RECIST v1.1, Up to approximately 41 months|Time to intracranial progressions as per BICR according to RECIST v1.1, Up to approximately 41 months|Number of participants with Adverse Events (AEs), Serious AEs (SAEs), AEs leading to study intervention discontinuation, and drug-related AEs, Up to 30 days after last dose|Number of deaths, Up to 30 days after last dose|Number of participants without at least a 3-point change in the Non-Small Cell Lung Cancer-Symptom Assessment Questionnaire (NSCLC-SAQ) total score, Up to 30 days after last dose
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).